Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma

The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.

NCT Number	NCT07611149
Lead Sponsor	Kure Cells, INC Collaborators: CellServe LLC, Roya Clinical
Conditions	Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Enrollment	12 participants
Start Date	2026-09-01
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-28